Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1992 May;65(5):661–666. doi: 10.1038/bjc.1992.141

Effects of intraperitoneal recombinant interleukin-1 beta in intraperitoneal human ovarian cancer xenograft models: comparison with the effects of tumour necrosis factor.

S T Malik 1, N East 1, D Boraschi 1, F R Balkwill 1
PMCID: PMC1977379  PMID: 1586593

Abstract

The effect of intraperitoneal (i.p.) injection of recombinant human interleukin-1 beta (rhIL-1 beta) was studied in three i.p. nude mouse xenograft models of human ovarian cancer (HU, OS, and LA). Intraperitoneal rhIL-1 beta administration led to a dose dependent replacement of peritoneal ascitic tumour with solid tumours attached to the peritoneum and intraabdominal viscera in two (HU and LA) out of the three xenograft models. In the third xenograft model (OS), low doses of rhIL-1 beta (10 ng day) promoted micrometastatic peritoneal implants of tumour, but higher doses of rhIL-1 beta (1 microgram day) had a marked antitumour effect. This was due to direct cytotoxicity for tumour cells and was not related to peritoneal neutrophil influx induced by rhIL-1 beta. Recombinant human TNF (rhTNF) also promoted tumour implantation in all three xenograft models, but its antitumour effects differed from rhIL-1 beta. TNF increased the survival of HU and LA bearing mice, but had no antitumour effect in the OS xenograft model. Analysis of peritoneal fluid and tumour xenografts showed that TNF induced murine IL-1 in the tumour bearing mice. The magnitude of IL-1 induction indicated that TNF induced IL-1 did not contribute significantly to its effects.

Full text

PDF
661

Images in this article

664Figure 4
on p.664
665Figure 6
on p.665

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Asher A., Mulé J. J., Reichert C. M., Shiloni E., Rosenberg S. A. Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J Immunol. 1987 Feb 1;138(3):963–974. [PubMed] [Google Scholar]
  2. Balkwill F. R., Lee A., Aldam G., Moodie E., Thomas J. A., Tavernier J., Fiers W. Human tumor xenografts treated with recombinant human tumor necrosis factor alone or in combination with interferons. Cancer Res. 1986 Aug;46(8):3990–3993. [PubMed] [Google Scholar]
  3. Balkwill F. R., Moodie E. M., Freedman V., Fantes K. H. Human interferon inhibits the growth of established human breast tumours in the nude mouse. Int J Cancer. 1982 Aug 15;30(2):231–235. doi: 10.1002/ijc.2910300217. [DOI] [PubMed] [Google Scholar]
  4. Bani M. R., Garofalo A., Scanziani E., Giavazzi R. Effect of interleukin-1-beta on metastasis formation in different tumor systems. J Natl Cancer Inst. 1991 Jan 16;83(2):119–123. doi: 10.1093/jnci/83.2.119. [DOI] [PubMed] [Google Scholar]
  5. Belardelli F., Ciolli V., Testa U., Montesoro E., Bulgarini D., Proietti E., Borghi P., Sestili P., Locardi C., Peschle C. Anti-tumor effects of interleukin-2 and interleukin-1 in mice transplanted with different syngeneic tumors. Int J Cancer. 1989 Dec 15;44(6):1108–1116. doi: 10.1002/ijc.2910440629. [DOI] [PubMed] [Google Scholar]
  6. Braunschweiger P. G., Johnson C. S., Kumar N., Ord V., Furmanski P. Antitumor effects of recombinant human interleukin 1 alpha in RIF-1 and Panc02 solid tumors. Cancer Res. 1988 Nov 1;48(21):6011–6016. [PubMed] [Google Scholar]
  7. Chirgwin J. M., Przybyla A. E., MacDonald R. J., Rutter W. J. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry. 1979 Nov 27;18(24):5294–5299. doi: 10.1021/bi00591a005. [DOI] [PubMed] [Google Scholar]
  8. De Jaco P., Asselain B., Orlandi C., Fridman W. H., Teillaud J. L. Evaluation of circulating tumor necrosis factor-alpha in patients with gynecological malignancies. Int J Cancer. 1991 May 30;48(3):375–378. doi: 10.1002/ijc.2910480311. [DOI] [PubMed] [Google Scholar]
  9. Dinarello C. A. Interleukin-1 and interleukin-1 antagonism. Blood. 1991 Apr 15;77(8):1627–1652. [PubMed] [Google Scholar]
  10. Elias J. A., Reynolds M. M., Kotloff R. M., Kern J. A. Fibroblast interleukin 1 beta: synergistic stimulation by recombinant interleukin 1 and tumor necrosis factor and posttranscriptional regulation. Proc Natl Acad Sci U S A. 1989 Aug;86(16):6171–6175. doi: 10.1073/pnas.86.16.6171. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Feinberg A. P., Vogelstein B. "A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity". Addendum. Anal Biochem. 1984 Feb;137(1):266–267. doi: 10.1016/0003-2697(84)90381-6. [DOI] [PubMed] [Google Scholar]
  12. Gearing A. J., Bird C. R., Bristow A., Poole S., Thorpe R. A simple sensitive bioassay for interleukin-1 which is unresponsive to 10(3) U/ml of interleukin-2. J Immunol Methods. 1987 May 4;99(1):7–11. doi: 10.1016/0022-1759(87)90025-1. [DOI] [PubMed] [Google Scholar]
  13. Gelin J., Moldawer L. L., Lönnroth C., Sherry B., Chizzonite R., Lundholm K. Role of endogenous tumor necrosis factor alpha and interleukin 1 for experimental tumor growth and the development of cancer cachexia. Cancer Res. 1991 Jan 1;51(1):415–421. [PubMed] [Google Scholar]
  14. Giavazzi R., Garofalo A., Bani M. R., Abbate M., Ghezzi P., Boraschi D., Mantovani A., Dejana E. Interleukin 1-induced augmentation of experimental metastases from a human melanoma in nude mice. Cancer Res. 1990 Aug 1;50(15):4771–4775. [PubMed] [Google Scholar]
  15. Haranaka K., Satomi N., Sakurai A. Antitumor activity of murine tumor necrosis factor (TNF) against transplanted murine tumors and heterotransplanted human tumors in nude mice. Int J Cancer. 1984 Aug 15;34(2):263–267. doi: 10.1002/ijc.2910340219. [DOI] [PubMed] [Google Scholar]
  16. Kilian P. L., Kaffka K. L., Biondi D. A., Lipman J. M., Benjamin W. R., Feldman D., Campen C. A. Antiproliferative effect of interleukin-1 on human ovarian carcinoma cell line (NIH:OVCAR-3). Cancer Res. 1991 Apr 1;51(7):1823–1828. [PubMed] [Google Scholar]
  17. Kovacs E. J. Fibrogenic cytokines: the role of immune mediators in the development of scar tissue. Immunol Today. 1991 Jan;12(1):17–23. doi: 10.1016/0167-5699(91)90107-5. [DOI] [PubMed] [Google Scholar]
  18. Le J., Vilcek J. Tumor necrosis factor and interleukin 1: cytokines with multiple overlapping biological activities. Lab Invest. 1987 Mar;56(3):234–248. [PubMed] [Google Scholar]
  19. Lichtenstein A., Seelig M., Berek J., Zighelboim J. Human neutrophil-mediated lysis of ovarian cancer cells. Blood. 1989 Aug 1;74(2):805–809. [PubMed] [Google Scholar]
  20. Malik S. T., Griffin D. B., Fiers W., Balkwill F. R. Paradoxical effects of tumour necrosis factor in experimental ovarian cancer. Int J Cancer. 1989 Nov 15;44(5):918–925. doi: 10.1002/ijc.2910440529. [DOI] [PubMed] [Google Scholar]
  21. Malik S. T., Naylor M. S., East N., Oliff A., Balkwill F. R. Cells secreting tumour necrosis factor show enhanced metastasis in nude mice. Eur J Cancer. 1990;26(10):1031–1034. doi: 10.1016/0277-5379(90)90044-t. [DOI] [PubMed] [Google Scholar]
  22. Malik S., Balkwill F. Epithelial ovarian cancer: a cytokine propelled disease? Br J Cancer. 1991 Oct;64(4):617–620. doi: 10.1038/bjc.1991.372. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Nakamura S., Nakata K., Kashimoto S., Yoshida H., Yamada M. Antitumor effect of recombinant human interleukin 1 alpha against murine syngeneic tumors. Jpn J Cancer Res. 1986 Aug;77(8):767–773. [PubMed] [Google Scholar]
  24. Nawroth P. P., Bank I., Handley D., Cassimeris J., Chess L., Stern D. Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1. J Exp Med. 1986 Jun 1;163(6):1363–1375. doi: 10.1084/jem.163.6.1363. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Naylor M. S., Malik S. T., Stamp G. W., Jobling T., Balkwill F. R. In situ detection of tumour necrosis factor in human ovarian cancer specimens. Eur J Cancer. 1990;26(10):1027–1030. doi: 10.1016/0277-5379(90)90043-s. [DOI] [PubMed] [Google Scholar]
  26. Onozaki K., Matsushima K., Aggarwal B. B., Oppenheim J. J. Human interleukin 1 is a cytocidal factor for several tumor cell lines. J Immunol. 1985 Dec;135(6):3962–3968. [PubMed] [Google Scholar]
  27. Palladino M. A., Jr, Shalaby M. R., Kramer S. M., Ferraiolo B. L., Baughman R. A., Deleo A. B., Crase D., Marafino B., Aggarwal B. B., Figari I. S. Characterization of the antitumor activities of human tumor necrosis factor-alpha and the comparison with other cytokines: induction of tumor-specific immunity. J Immunol. 1987 Jun 1;138(11):4023–4032. [PubMed] [Google Scholar]
  28. Philip R., Epstein L. B. Tumour necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself, gamma-interferon and interleukin-1. Nature. 1986 Sep 4;323(6083):86–89. doi: 10.1038/323086a0. [DOI] [PubMed] [Google Scholar]
  29. Ruggiero V., Baglioni C. Synergistic anti-proliferative activity of interleukin 1 and tumor necrosis factor. J Immunol. 1987 Feb 1;138(3):661–663. [PubMed] [Google Scholar]
  30. Sato K., Fujii Y., Ono M., Nomura H., Shizume K. Production of interleukin 1 alpha-like factor and colony-stimulating factor by a squamous cell carcinoma of the thyroid (T3M-5) derived from a patient with hypercalcemia and leukocytosis. Cancer Res. 1987 Dec 15;47(24 Pt 1):6474–6480. [PubMed] [Google Scholar]
  31. Shau H. Cytostatic and tumoricidal activities of tumor necrosis factor-treated neutrophils. Immunol Lett. 1988 Jan;17(1):47–51. doi: 10.1016/0165-2478(88)90100-9. [DOI] [PubMed] [Google Scholar]
  32. Takeyama H., Wakamiya N., O'Hara C., Arthur K., Niloff J., Kufe D., Sakarai K., Spriggs D. Tumor necrosis factor expression by human ovarian carcinoma in vivo. Cancer Res. 1991 Aug 15;51(16):4476–4480. [PubMed] [Google Scholar]
  33. Tsai S. C., Gaffney E. V. Inhibition of cell proliferation by interleukin-1 derived from monocytic leukemia cells. Cancer Res. 1986 Mar;46(3):1471–1477. [PubMed] [Google Scholar]
  34. Ward B. G., Wallace K., Shepherd J. H., Balkwill F. R. Intraperitoneal xenografts of human epithelial ovarian cancer in nude mice. Cancer Res. 1987 May 15;47(10):2662–2667. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES